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Abstract
Brucellosis is considered a zoonotic disease which is still an important health problem in
endemic areas such as the Middle East, the Mediterranean, and Asia. Brucellosis is a sys‐
temic infection that might affect any organ or system in the body. Ocular involvement
has been reported in 21% of brucellosis patients. The most common ocular manifestations
of brucellosis were considered as anterior uveitis and choroiditis. The patients with ante‐
rior uveitis were reported to be usually in the acute stage and the patients with choroidi‐
tis, papilledema, and posterior uveitis were reported to be usually in the chronic stage of
the disease. Ocular manifestations of brucellosis might also involve dacryoadenitis, con‐
junctivitis, episcleritis, scleritis, nummular keratitis, cataract, glaucoma, exudative retinal
detachment, maculopathy, and neuro-ophthalmic defects including papilledema, papilli‐
tis, and cranial nerve paresis. Optic nerve involvement in brucellosis is considered secon‐
dary to meningeal inflammation, and it usually involves both optic nerves. Premacular
hemorrhage related to Brucella endocarditis was reported as a rare ocular manifestation.
Since ocular brucellosis has a wide spectrum of clinical manifestations, the diagnosis is
considered to be mainly dependent on positive bacteriological and serological tests. Ag‐
glutinations and/or culture has been widely used for diagnosis of brucellosis. Brucella ag‐
glutination test over 1/160 titer and positive blood culture are considered as diagnostic
factors for brucellosis. Early diagnosis and prompt treatment are considered to be effec‐
tive for preventing blindness from severe ocular damage. Systemic antibiotics including
streptomycine, rifampicin, doxycycline along with topical or systemic corticosteroid
treatment have been recommended for at least 2 months. The purpose of this chapter is to
describe the ocular manifestations of brucellosis, early diagnostic procedures, and treat‐
ment with reviewing the literature.
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1. Introduction
Brucellosis is considered a common zoonotic disease that has been reported to cause more than
500,000 new human cases worldwide annually [1,2]. It is still more prevalent in some parts of
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the world, especially Middle East countries including Iran, Saudi Arabia, Kuwait, Turkey, the
Mediterranean, Mexico, and Central and South America [3-6]. Brucella melitensis has been
reported as the most common and virulent species in endemic countries [7]. B. abortus has been
seen mostly in Europe and North America [7]. B. canis causes canine brucellosis with intraoc‐
ular inflammation, and B. suis infects domestic pigs [7].
2. Ocular manifestations
Brucellosis  has  unusual  clinical  manifestations,  and the  clinical  presentation might  vary
from asymptomatic infection to a full-blown clinical picture of fever, night sweats, and joint
manifestations; rarely, there is hepatic, cardiac, ocular, or central nervous system involve‐
ment [8]. Since there is no pathognomonic sign of ocular involvement caused by brucello‐
sis, it remains poorly recognized in areas where brucellosis is endemic [9]. In a large series
including 1551 patients with brucellosis from Peru during a period of 26 years, 52 (3.3%)
patients have been diagnosed with ocular brucellosis [10]. Both acute and chronic brucello‐
sis have been reported to cause ocular involvement [10]. All the ocular structures might be
affected  by  brucellosis  [9,11].  However,  the  most  frequent  ocular  presentation  has  been
reported as uveitis [12,13]. Uveitis has been reported between 21 and 67% of patients with
ocular  brucellosis  in  the previous studies  [12-14].  The following presentations of  uveitis
might be identified: anterior uveitis, including iritis, and iridocyclitis; intermediate uveitis,
including pars planitis and vitritis; posterior uveitis, including choroiditis, chorioretinitis,
retinitis, and neuroretinitis; and panuveitis, including inflammation of all 3 components of
the uveal tract [11-15]. The most frequent presentation of uveitis in ocular brucellosis has
been considered as  posterior  uveitis  [16].  Patients  with  panuveitis  had the  worst  visual
prognosis  [16,17].  In  a  case  series,  8  of  9  patients  with  panuveitis  were  legally  blind,
including 5 patients with no light perception [17]. In a cohort study from Turkey includ‐
ing 132 patients with brucellosis, anterior uveitis was the most frequent manifestation with
a frequency of 41%, followed by choroiditis (32%), panuveitis (9%), papilledema (9%), and
retinal hemorrhages (9%) [12]. 41% of the patients with ocular involvement were found in
the acute stage and 59% were in the chronic stage of brucellosis [12]. In this study, all the
patients  with  anterior  uveitis  were  reported  to  be  in  the  acute  stage,  and all  the  other
patients with choroiditis, papilledema, and retinal hemorrhages were reported to be in the
chronic stage of the disease. [12] In another cohort study from Turkey including 147 patients
with the diagnosis of brucellosis, 38 patients (26.0%) had ocular manifestations including
conjunctivitis  in  26  (17.7%),  anterior  uveitis  in  6  (4.1%),  posterior  uveitis  in  1  (0.7%),
dacryoadenitis in 2 (1.4%),  and episcleritis  in 3 (2.1%) of patients [18].  Brucellosis might
have unusual ocular manifestations [17,19,20] such as: recurrent episcleritis associated with
brucellosis has been reported as a rare occurrence from Turkey and France [19,20]. A rare
presentation of brucellosis has also been reported as bilateral optic nerve, right abducent
nerve involvement, and endocarditis complicated by right premacular hemorrhage in a 28-
year-old white female from Turkey [21]. Bilateral multifocal choroiditis with serous retinal
detachment in a patient with Brucella  infection has been reported from USA considering
Updates on Brucellosis70
Vogt-Koyanagi-Harada  (VKH)  syndrome,  which  is  characterized  by  bilateral  panuveitis
associated  with  bilateral  retinal  detachments  spontaneously  resolving,  as  differential
diagnosis [17].
3. Pathogenesis and diagnosis
The infection was rapidly controlled at the site of inoculation but resulted in a local and
systemic dissemination of Brucella mainly in the pharyngeal tonsil, local and peripheral lymph
nodes, and the spleen [24]. The control of the infection is considered to be associated with the
induction of a specific immune response characterized by an increase in IgG producing B-cells,
the production of IFN- gamma, and IL-10 by cells from draining parotid, retropharyngeal, and
submaxillary lymph nodes, but also from more distant peripheral lymph nodes.[24] IFN-
gamma is produced by CD4+, CD8+, and CD4(-)CD8(-) gamma delta(-) cells, and probably
contributed to the control of both local and systemic infection [25]. Human brucellosis is
diagnosed by clinical criteria, isolation of the causative agent from blood or tissue cultures
with a positivity rate of 40-70%, or by using serologic techniques as complementary tools. Rose
Bengal Plate Test (RBPT) and serum agglutination test (SAT) are the most widely used
serologic tests [26]. The sensitivity of RBPT is considered high, but its specificity is low for
testing individuals residing in an endemic area [26]. SAT is used to confirm RBPT results. It
has limitations of lack of sensitivity as well as specificity [27-29]. Recently, molecular biology
diagnostic techniques have been developed, intending to optimize the etiological confirmation
[30]. Polymerase chain reaction (PCR) amplification-based methods are being used effectively
in the detection of brucellosis [31]. They are considered safer than culture-based methods for
the staff [31]. Intraocular serological tests are used to support the diagnosis of ocular brucellosis
[14,32]. The Goldmann-Witmer coefficient, which is the ratio of intraocular to serum IgG
production against the Brucella organism, is usually determined by analyzing the serum and
intraocular fluid agglutinations for Brucella [14,33,34]. The diagnosis is usually confirmed with
a high Brucella agglutination titer in the vitreous specimen [33]. The sensitivity of the Gold‐
mann-Witmer analysis has been reported as 66.7% and the specificity was 100% [14].
4. Differential diagnosis
Ocular involvement of brucellosis should be differentially diagnosed from tuberculosis,
syphilis, toxoplasmosis, toxocariasis, sarcoidosis, behcet’s disease, Vogt-Koyanagi-Harada
syndrome, and multifocal choroiditis [16,17,32]. No pathognomonic sign of ocular involve‐
ment of brucellosis has been reported. However, acute form of brucellosis is usually presented
as fever, headache, sweating, lower back pain, and organomegaly [9]. Ocular involvement in
acute form has been reported usually in the form of bilateral acute anterior uveitis, which might
be associated with episcleritis and scleritis [10]. Posterior uveitis followed by panuveitis
associated with papillitis and retinal hemorrhages were considered the most common ocular
manifestations of chronic brucellosis [10]. Neuro-ophthalmologic signs, including the cranial
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nerves involved in ocular movements, were also reported to be more common in chronic
brucellosis [34].
5. Complications
Ocular brucellosis might lead to blindness from severe ocular damage in patients having late
diagnosis and improper treatment. The following complications have been reported: cataracts,
glaucoma, maculopathy, vitreal alterations, phthisis bulbi, optic atrophy, neovascular retinal
membrane, and tractional retinal detachment [18,32].
6. Treatment
Ophthalmic manifestations of brucellosis are usually treated with both antibiotics and steroids
[35]. Cavallarro et al. reported a patient with papilledema due to brucellosis that was treated
with sole anti-brucellosis treatment without steroid administration [36]. Abd Elrazak reported
a case of bilateral optic neuritis caused by brucellosis that resolved following anti-brucellosis
and steroid administration [37]. Sahin et al. reported the resolution of unilatreral papillitis and
premacular hemorrhage with antibiotics and intravenous high-dose steroid followed by oral
steroid administration for 3 months [21]. The tetracyclines remain the most active and clinically
effective antibiotics for the treatment of brucellosis [38]. Doxycycline is now the preferred
tetracycline analogue for treating human brucellosis [38]. The use of tetracyclines as mono‐
therapy for human brucellosis is complicated by a relapse rate between 8 and 39% [38]. The
high relapse rates are dramatically reduced when doxycycline is combined with other drugs,
such as streptomycin (relapse rate 4.5%) or rifampicin (relapse rate 8.4%) [38]. Streptomycin
in combination with tetracycline or doxycycline has been the "gold standard" for comparison
of other antibiotic regimens for the treatment of human brucellosis [38]. A major drawback to
the use of tetracyclines is the permanent staining of teeth in young children [39]. Consequently,
tetracyclines are contraindicated for brucellosis in pregnant women and children under 8 years
of age [39,40]. In this regard, doxycycline binds less to calcium than do other tetracyclines and
may cause dental complications less frequently [41]. Cotrimoxazole is a useful alternative in
the treatment of brucellosis when the use of tetracyclines is contraindicated [42,43]. Although,
rifampin has been used as monotherapy in brucellosis relapses, and the emergence of rifampin-
resistant strains have led to its use primarily in combination with other drugs [38]. Results
have been generally disappointing in monotherapy with quinolones, which were used to treat
human brucellosis [38]. In a study from Turkey, 21 patients received ofloxacin (200 mg twice
daily) for varying periods of time; the relapse rate was 16% [44]. In contrast, a group of patients
in Israel treated with ciprofloxacin (750 or 1000 mg twice daily) for 6 weeks had a relapse rate
of 66% [45]. Similarly, another study from Turkey reported 12 patients treated with ciproflox‐
acin (500 mg thrice daily) for 3 to 6 weeks, with a relapse rate of 21% [46]. Consequently,
monotherapy of brucellosis with quinolones is not recommended, and they should be used in
combination with other antimicrobials [38, 47]. The combination of doxycycline for 6 weeks
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plus streptomycin for 2 to 3 weeks remains the most frequently used and most effective
treatment for human brucellosis [47]. Most authorities consider that gentamicin (5 mg/kg/day)
intravenously or intramuscularly as a single injection can be used in place of streptomycin;
however, the duration of gentamicin administration is unclear [48]. Although 5- and 7- day
regimens of gentamicin have been used, we advise no fewer than 10 days [48]. In summary,
many clinicians prefer to administer rifampin (600-900 mg/day orally) for the remainder of the
6 weeks after discontinuing gentamicin, but this regimen has not been studied in comparative
trials. The second-choice regimen consists of doxycycline (200 mg/day orally) plus rifampin
(600-900 mg/day orally), with both drugs administered for 45 days.
7. Conclusions
Ocular involvement in acute or chronic brucellosis is still prevalent in endemic countries. A
wide range of ocular manifestations have been described for brucellosis. However, uveitis and
neuro-ophthalmic manifestations are the most common presentations. Diagnosis of ocular
brucellosis mainly depends on culture and serology of blood and intraocular fluids. Early
diagnosis and prompt treatment might restore the vision in ocular involvement.
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